Skip to main content
SpringerLink
Log in

The increasing role of Acinetobacter species as nosocomial pathogens

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Among gram-negative organisms playing a significant role in nosocomial infections, Acinetobacter species have attracted increasing attention in intensive care units during the past two decades. Acinetobacter species are implicated in a wide spectrum of infections (eg, bacteremia, nosocomial pneumonia, urinary tract infections, secondary meningitis, superinfections in burn patients). One of the most striking features of Acinetobacter species is their extraordinary ability to develop multiple resistance mechanisms against major antibiotic classes. They have become resistant to broad-spectrum β-lactams (third-generation cephalosporins, carboxypenicillins, and increasingly to carbapenems); they produce a wide range of aminoglycoside-inactivating enzymes; and most strains are resistant to fluoroquinolones. In Acinetobacter nosocomial infections, the major problems confronting clinicians in intensive care units are related to the severity of Acinetobacter nosocomial infections and to resistance to major antibiotic classes of these organisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Joly-Guillou ML, Brun-Buisson C, Epidemiology of Acinetobacter spp: surveillance and management of outbreaks. In Acinetobacter: Microbiology, Epidemiology, Infection, Management. Edited by Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ, New York: CRC Press; 1996:71–100.

    Google Scholar 

  2. Levi I, Rubinstein E, Acinetobacter infections. Overview of clinical features. In Acinetobacter: Microbiology, Epidemiology, Infection, Management. Edited by Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ, New York: CRC Press; 1996:101–115.

    Google Scholar 

  3. Villers D, Espaze E, Coste-Burel M, et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998, 129:182–189.

    PubMed  CAS  Google Scholar 

  4. Wolff M, Brun-Buisson C, Lode H, The changing epidemiology of severe infections in the ICU. Clin Microbiol Infect 1997, 3,suppl 1,:S36-S47. An interesting and well documented review on changing patterns of epidemiology of nosocomial pathogens, pointing out the growing importance of Acinetobacter species with the therapeutic impact of these changes.

    Article  Google Scholar 

  5. Fiérobe L, Lucet JC, Decré D, et al. An outbreak of imipenemresistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 2001, 22:35–40. A French experience on outbreaks of Acinetobacter infections in a surgical ICU, including 17 cases with imipenem-resistant strains typed by PFGE that detected two clones of the pathogen. A casecontrol epidemiologic study with multivariate analysis (score TISS) demonstrated the role of multiple management techniques and risk factors.

    Article  Google Scholar 

  6. Jimenez-Mejias ME, Pachon J, Becerril B, et al. Treatment of multidrug resistant Acinetobacter baumannii meningitis with ampicillin-sulbactam. Clin Infect Dis 1999, 24:932–935.

    Google Scholar 

  7. Koeleman JG, Parleviet GA, Dijskhoorn L, et al. Nosocomial outbreak of mutiresistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect 1997, 37:113–123.

    Article  PubMed  CAS  Google Scholar 

  8. Weinbren MJ, Johnson A, Kaufmann ME, Livermore DM, Acinetobacter spp isolates with reduced susceptibilities to carbapenems in a UK burns unit. J Antimicrob Chemother 1998, 41:574–576.

    Article  PubMed  CAS  Google Scholar 

  9. Freeman R, Sisson PR, Noble WC, Lightfoot NF, An apparent outbreak of infection with Acinetobacter calcoaceticus reconsidered after investigation by pyrolisis mass spectrometry. Zentralbl Bakteriol 1997, 285:234–244.

    PubMed  CAS  Google Scholar 

  10. Chastre J, Trouillet JL, Vuagnat A, Joly-Guillou, Nosocomial pneumonia caused by Acinetobacter spp. In Acinetobacter: Microbiology, Epidemiology, Infection, Management. Edited by Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ, New York: CRC Press; 1996:117–132.

    Google Scholar 

  11. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999, 28:1008–1011.

    Article  PubMed  CAS  Google Scholar 

  12. Garcia-Garmendia JL, Ortiz-Lyba C, Garnacho-Montero J, et al. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999, 27:1794–1799. A case-control study showing the impact of A. baumannii acquisition in ICU on the length of stay, contrasting with the usual approach of Acinetobacter pneumonia increasing in relation to the length of stay.

    Article  PubMed  CAS  Google Scholar 

  13. Kollef MH, Sherman G, Ward S, Fraser VJ, Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462–474.

    Article  PubMed  CAS  Google Scholar 

  14. Hunt JP, Buechter KJ, Fahry SM, Acinetobacter calcoaceticus pneumonia and the formation of pneumatoceles. J Trauma Injury Infect Crit Care 2000, 48:964–970.

    Article  CAS  Google Scholar 

  15. Lai SW, Ng KC, Liu CS, et al. Acinetobacter baumannii bloodstream infection: clinical featrures and antimicrobial susceptibilities of isolates. Kaohsiung J Med Sci 1999, 15:406–413.

    PubMed  CAS  Google Scholar 

  16. Wisplinghoff H, Perbix W, Seifert H, Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999, 28:59–66.

    Article  PubMed  CAS  Google Scholar 

  17. Bergogne-Bérézin E, Towner KJ, Acinetobacter spp as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9:148–165.

    PubMed  Google Scholar 

  18. Dijkshoorn L, Acinetobacter microbiology. In Acinetobacter: Microbiology, Epidemiology, Infection, Management. Edited by Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ, New York: CRC Press; 1996:37–69.

    Google Scholar 

  19. Traub WH, Bauer D, Surveillance of nosocomial cross-infection due to three Acinetobacter genospecies (Acinetobacter baumannii, genospecies 3 and genospecies 13) during a 10-year observation period: serotyping, macrrorestriction analysis of genomic DNA and antibiotic susceptibilities. Chemotherapy 2000, 46:282–292.

    Article  PubMed  CAS  Google Scholar 

  20. Goncalves CR, Vaz TM, Araujo E, et al. Biotyping, serotyping and ribotyping as epidemiological tools in the evaluation of Acinetobacter baumanii dissemination in hospital units. J Med Microbiol 2000, 49:773–778. A comprehensive review of typing updated techniques for typing of A. baumannii strains based on experience of dissemination of the organism in hospital units in Brazil.

    Google Scholar 

  21. Husni RN, Goldstein LS, Arroliga AC, et al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999, 115:1378–1382. An interesting epidemiologic case-control study in an ICU of Acinetobacter infection with an epidemic strain (molecular typing by PFGE on bloodstream isolates). Univariate analysis showed that prior use of ceftazidime was significantly associated with Acinetobacter infection (78.5%) versus control (37.9%).

    Article  PubMed  CAS  Google Scholar 

  22. Yu EH, Ko WC, Chuang YC, Wu TJ, Suppurative thyroiditis with bacteremic pneumonia: case report and review. Clin Infect Dis 1998, 27:1286–1290.

    Article  PubMed  CAS  Google Scholar 

  23. Lopez-Hernandez S, Alarcon T, Lopez-Brea M, Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain. J Clin Microbiol Infect Dis 1998, 17:282–285.

    Article  CAS  Google Scholar 

  24. Mishra A, Mishra S, Jaganath G, et al. Acinetobacter sepsis in new-borns. Indian Pediatrics 1998, 35:27–32.

    PubMed  CAS  Google Scholar 

  25. Caputo R, Gelmetti C, Cambaghi S, Severe self healing nail dystrophy in a patient on peritoneal dialysis. Dermatology 1997, 195:274–275.

    Article  PubMed  CAS  Google Scholar 

  26. Lam SM, Huang TY, Acinetobacter with tamponade in a patient with systemic lupus erythematosus. Lupus 1997, 6:480–483.

    Article  PubMed  CAS  Google Scholar 

  27. Mc Donald LC, Walker M, Carson L, et al. Outbreak of Acinetobacter spp bloodstream infection in a nursery associated with contaminated aerosols and air conditioners. Pediatr Infect Dis J 1998, 17:716–722. One of the recent studies confirming occurrence of Acinetobacter infection in children and neonates, less rare than seen previously. In this particular study, involving 33 infant infections, a polyclonal airborne dissemination occurred in an area with humid and warm weather (Bahamas), a known risk factor for Acinetobacter acquisition.

    Article  Google Scholar 

  28. Nagels B, Ritter E, Thomas P, et al. Acinetobacter baumannii colonization in ventilated preterm infants. Eur J Clin Microbiol Infect Dis 1998, 17:37–40. Pointing out the occurrence of Acinetobacter infection in children, this interesting investigation in preterm infants showed the role of ventilation, birth weigth, and gestational age in Acinetobacter infection in a pediatric ICU.

    Article  PubMed  CAS  Google Scholar 

  29. Pillay T, Pillay DG, Adhikari M, et al. An outbreak of neonatal infection with Acinetobacter linked to contaminated suction catheters. J Hosp Infect 1999, 43:299–304.

    Article  PubMed  CAS  Google Scholar 

  30. Somerville DA, Noble WC, A note on the gram-negative bacilli of human skin. Eur J Clin Biol Res 1970, 40:669–670.

    Google Scholar 

  31. Ayats J, Corbella X, Ardanuy C, et al. Epidemiological significance of cutaneous, pharyngeal and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect 1997, 37:287–295.

    Article  PubMed  CAS  Google Scholar 

  32. Joly-Guillou ML, Bergogne-Bérézin E, Philippon A, Distribution of b-lactamases and phenotype analysis in clinical strains of Acientobacter calcoaceticus. J Antimicrob Chemother 1988, 22:773–775.

    Article  Google Scholar 

  33. Amyes SGB, Young HK, Mechanisms of antibiotic resistance in Acinetobacter spp.: genetics of resistance. In Acinetobacter: Microbiology, Epidemiology, Infection, Management. Edited by Bergogne-Bérézin E, Joly-Guillou ML, Towner KJ, New-York: CRC Press; 1996:185–223.

    Google Scholar 

  34. Afzal-Shah M, Livermore DM, Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998, 41:576–577.

    Article  PubMed  CAS  Google Scholar 

  35. Afzal-Shah M, Woodford N, Livermore DM, Characterization of OXA-25, OXA-26, and OXA-27, Molecular classes D β-Lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001, 45:583–588. One of the most recent comprehensive updates on the enlarging range of OXA-b-lactamases associated with carbapenem resistance that Acinetobacter species can produce in hospitals.

    Article  Google Scholar 

  36. Bou G, Oliver A, Martinez-Beltran J, OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 2000, 44:1556–1561.

    Article  PubMed  CAS  Google Scholar 

  37. Moreau NJ, Houot S, Joly-Guillou ML, Bergogne-Bérézin E, Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones. J Antimicrob Chemother 1996, 38:1079–1083.

    Article  PubMed  CAS  Google Scholar 

  38. Horrevorts A, Ten Hagen G, Hekster Y, et al. Development of resistance to ciprofloxacin in Acinetobacter baumannii strains isolated during a 20-month outbreak. J Antimicrob Chemother 1997, 40:460–461.

    Article  PubMed  CAS  Google Scholar 

  39. Brisse S, Milatocic D, Fluit AC, et al. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp using automated ribotyping. J Clin Microbiol 2000, 38:3636–3645. This study highlights a remarkable approach for resistance surveillance: collecting strains from 23 European hospitals and investigating the clonal diversity by automated ribotyping among fluoroquinolone-resistant isolates (resistant to sitafloxacin, a new advanced quinolone). Other antibiotics classes tested showed the presence of multiresistant international clones. This study shows the potential for establishing a library typing system for monoitoring future epidemiologic studies.

    PubMed  CAS  Google Scholar 

  40. Rodriguez-Hernandez MJ, Pachon J, Pichardo C, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter experimental pneumonia. J Antimicrob Chemother 2000, 45:493–501.

    Article  PubMed  CAS  Google Scholar 

  41. Corbella X, Ariza J, Ardanuy C, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998, 42:793–802.

    Article  PubMed  CAS  Google Scholar 

  42. Wolff M, Joly-Guillou ML, Farinotti R, Carbon C, In vivo efficacies of combonations of b-lactams, b-lactamaseinhibitors and rifampicin gainst Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999, 43:1406–1411.

    PubMed  CAS  Google Scholar 

  43. Rodiguez-Hernandez MJ, Cuberos L, Pichardo C, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 2001, 47:479–482.

    Article  Google Scholar 

  44. Joly-Guillou ML, Wolff M, Farinotti R, et al. In vivo activity of levofloxacin alone or in combiantion with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother 2000, 46:827–830.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine Bichat, University Paris, 100 bis rue du Cherche-Midi, 75006, Paris, France

    Eugénie Bergogne-Bérézin

Authors
  1. Eugénie Bergogne-Bérézin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergogne-Bérézin, E. The increasing role of Acinetobacter species as nosocomial pathogens. Curr Infect Dis Rep 3, 440–444 (2001). https://doi.org/10.1007/BF03160479

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03160479

Keywords

Search

Navigation